WATERTOWN, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 1:30 p.m. Eastern Time at The St. Regis New York Hotel in New York City.

A live audio webcast of the JMP presentation will be available on the company's website at http://ir.tphase.com/events.cfm.  An archived presentation will be available for 30 days.

About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes eravacycline, its lead antibiotic candidate in phase 3 clinical trials, as well as two additional antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.

Investor Contacts:
Tetraphase Pharmaceuticals
Teri Dahlman
617-600-7040
tdahlman@tphase.com

Argot Partners
Susan Kim
212-600-1902
susan@argotpartners.com

Media Contact:
Sam Brown Inc.
Mike Beyer 
312-961-2502
mikebeyer@sambrown.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.